Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection.
Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection.
复制标题
血小板源性sCD40 L：早期严重急性呼吸综合征冠状病毒2感染的特异性炎症标志物
DOI：
10.1186/s12985-021-01680-3
复制
发表时间：
2021-10-29
期刊：
影响因子：
4.8
通讯作者：
Cognasse F
中科院分区：
文献类型：
--
作者：
Hamzeh-Cognasse H;Mansour A;Reizine F;Mismetti P;Gouin-Thibault I;Cognasse F
SARS-CoV-2病毒是2019冠状病毒病（COVID-19）的致病因子，其特征是强烈的促炎反应和凝血功能障碍，严重时可能导致器官衰竭甚至死亡。作为血栓炎症的主要参与者，血小板释放大量免疫调节分子并调节白细胞和内皮细胞的活性，这在COVID-19中都发生了改变。总之，这使得血小板很可能成为COVID-19血栓炎性并发症的一个因素。因此，我们建议鉴定严重COVID-19在整个疾病过程中特异性调节的血小板炎症特征。采用Luminex技术和酶联免疫吸附法评估重症急性呼吸综合征冠状病毒2型感染患者入院时及入院后14 d血浆血小板炎症标志物水平。根据其他团队的观察，我们证明血小板可溶性CD40L的血浆水平在疾病的早期阶段显着升高。有趣的是，我们观察到sCD40L的血浆水平随着时间的推移而降低，而sCD62P的血浆水平显著升高。我们的数据表明，对SARS-COv-2感染的炎症反应存在血小板特征，该特征随着时间的推移而变化，可以作为患者炎症状态的监测生物标志物。临床试验注册号：2020-A01100-39；题目：COVID-19患者的人抗体反应和免疫监测，注册日期：05/25/2020；注册中心的URL: https://clinicaltrials.gov/ct2/history/NCT04373200?V_5=View。
The SARS-CoV-2 virus is the causing agent of the Coronavirus disease 2019 (COVID-19) characterized by a huge pro-inflammatory response and coagulation disorders that may lead to for its severe forms, in organ failure or even death. As major players of thrombo-inflammation, platelets release large amounts of immunomodulatory molecules and regulate leukocyte and endothelial activity, which are both altered in COVID-19. Altogether, this makes platelets a very likely actor of the thrombo-inflammatory complications of COVID-19. Thus, we propose to identify a platelet inflammatory signature of severe COVID-19 specifically modulated throughout the course of the disease. Luminex technology and enzyme-linked immunosorbent assay were used to assess plasma levels of platelet inflammatory markers in patients with severe acute respiratory syndrome coronavirus 2 infection on admission and for 14 days afterwards. In accordance with the observations of other teams, we evidence that the plasma levels of the platelet soluble (s)CD40L is significantly elevated in the early stages of the disease. Interestingly we observe that the plasma level of sCD40L decreases overtime while that of sCD62P increases significantly. Our data suggest that there is a platelet signature of inflammatory response to SARS-COv-2 infection which varies overtime and could serve as monitoring biomarkers of patient inflammatory state. Clinical trial registration number: 2020-A01100-39; title: Human Ab Response & immunoMONItoring of COVID-19 Patients, registration date: 05/25/2020; URL of the registry: https://clinicaltrials.gov/ct2/history/NCT04373200?V_5=View.
影响因子：
20.1
作者：
Zaid Y;Puhm F;Allaeys I;Naya A;Oudghiri M;Khalki L;Limami Y;Zaid N;Sadki K;Ben El Haj R;Mahir W;Belayachi L;Belefquih B;Benouda A;Cheikh A;Langlois MA;Cherrah Y;Flamand L;Guessous F;Boilard E
通讯作者：
Boilard E
影响因子：
9.8
作者：
Comer SP;Cullivan S;Szklanna PB;Weiss L;Cullen S;Kelliher S;Smolenski A;Murphy C;Altaie H;Curran J;O'Reilly K;Cotter AG;Marsh B;Gaine S;Mallon P;McCullagh B;Moran N;Ní Áinle F;Kevane B;Maguire PB;COCOON Study investigators
通讯作者：
COCOON Study investigators
DOI：
10.1161/atvbaha.120.314645
发表时间：
2021-01
期刊：
Arteriosclerosis, thrombosis, and vascular biology
影响因子：
--
作者：
Portier I;Campbell RA
通讯作者：
Campbell RA